Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million

In connection with Intellia Therapeutics’s acquisition of biotechnology startup Rewrite Therapeutics, Inc., Intellia engaged Finnegan to assess intellectual property (IP) issues as part of the due diligence efforts. The deal was valued at $45 million and involved Rewrite’s IP assets focused on DNA writing via CRISPR. Rewrite is also entitled to receive up to $155 million in potential pre-specified research and regulatory approval milestones.